Recursion Pharmaceuticals (RXRX) Stock Price
$5.03 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
2 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals has shown significant growth in revenue, with an increase of 226.9% from the previous quarter and a slight increase year over year. However, profitability is a concern as it reported negative gross profit and operating income, indicating that costs are exceeding revenues. The EBITDA ratio also suggests that the company is not currently profitable.
Stock Price
The stock price shows some volatility with an upward trend in the last month but a downward trend year over year. The RSI value at around mid-range suggests neither oversold nor overbought conditions. The current trading price is below its 200-day moving average, which could be seen as a bearish indicator.
Alternative Data Signals
Web traffic to Recursion's site has been decreasing both monthly and yearly, suggesting potentially lower public interest or engagement with the company online. Job openings have increased significantly on a monthly basis but decreased compared to last year. This could indicate fluctuating demand for talent within the company. Employee sentiment towards business outlook seems positive overall despite recent decreases.
Social media followers have grown substantially on both Twitter and Facebook in the past three months, which may suggest growing public awareness or interest in Recursion Pharmaceuticals.
Conclusion
In conclusion, while there are some positive signals such as revenue growth and social media engagement for Recursion Pharmaceuticals' stock performance, concerns about profitability and mixed alternative data signals lead to a somewhat bearish view on this stock.
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.03, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.78 0.5% |
6 |
 |
Inovio Pharmaceuticals INO |
$2.11 6.2% |
3 |
 |
Moderna MRNA |
$27.16 1.4% |
3 |
 |
Anavex Life Sciences AVXL |
$9.48 0.9% |
7 |
 |
BridgeBio Pharma BBIO |
$44.86 0.6% |
7 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 46681 monthly visitors to recursion.com.
-
Web Traffic
46681
-
Change from Previous Month
13.4%
-
3 Month Change
22.8%
-
YoY Change
22.8%
Twitter Followers
Recursion Pharmaceuticals has 14,653 Twitter Followers on its main Twitter (also known as X) account, which is up by 2.5% over the last month.
-
Twitter Followers
14653
-
Daily Change
0.2%
-
1 Month Change
2.5%
-
3 Month Change
4.4%
-
YoY Change
4.4%
Facebook Engagement
Recursion Pharmaceuticals has engaged 9 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
9
-
Daily Change
12.5%
-
1 Month Change
10%
-
3 Month Change
350%
-
YoY Change
350%
Youtube Subscribers
Recursion Pharmaceuticals has 3,900 subscribers on its main Youtube channel, up by 3.7% over the last month.
-
Youtube Subscribers
3900
-
Daily Change
0%
-
1 Month Change
3.7%
-
3 Month Change
11.1%
-
YoY Change
11.1%
Job Postings
Recursion Pharmaceuticals currenly has an estimated 23 open job postings, up by 76.9% over the last month.
-
Job Postings
23
-
Daily Change
0%
-
1 Month Change
76.9%
-
3 Month Change
20.7%
-
YoY Change
20.7%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 1 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 66 out of 100 (bullish), down by -12% over the last month.
-
Business Outlook
66
-
Change from Previous Month
12%
-
3 Month Change
9.6%
-
YoY Change
9.6%
News Mentions
Recursion Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$14.7M
-
Net Income
-$202.5M
-
Earnings per Share
-$0.5
-
Free cash flow
-$133.8M
-
EBITDA
-$191.4M
-
EBITDA Ratio
-12.9785
-
Total Assets
$1.3B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $5.03.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2B.
Should I buy or sell RXRX?
Recursion Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Recursion Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Recursion Pharmaceuticals a good investment?
The current analysis of Recursion Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Recursion Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Recursion Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $4.92 in 2026. Starting from the current price of $5.03, this represents a 2.3% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.